Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + Hyper-CVAD in Ph+ ALL
NCT01004497Phase 2Completed
- Sponsor
- The Catholic University of Korea
- Start
- Mar 2010
- Primary completion
- Apr 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by The Catholic University of Korea. Started Mar 2010; status: completed.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01004497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01004497.